BRIEF

on Viromed Medical AG (isin : DE000A3MQR65)

MHH to Unveil Cold Plasma Therapy Research for Lung Applications

On February 12, 2026, Hannover Medical School (MHH), in collaboration with the Helmholtz Centre for Infection Research (HZI), will host a press conference to present their scientific findings on cold plasma therapy for pulmonary use. The research, to be presented by Prof. Dr. Hortense Slevogt, highlights a novel treatment method targeting severe lung infections, an area of critical clinical demand globally.

Viromed Medical AG, the company behind the technology, views this development as strategically significant. The therapy addresses challenges posed by antibiotic-resistant pathogens, thus potentially transforming infection treatment. Pulmonary infections impact millions annually, emphasizing the urgency of new approaches like this scalable clinical application of cold plasma.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Viromed Medical AG news